Optimizing joint function: New knowledge and novel tools and treatments

Haemophilia

Volumn 18, Issue SUPPL.5, 2012, Pages 17-26

  Monahan, Paul E ^a   Doria, Andrea S ^b   Ljung, Rolf ^c   Jiménez Yuste, Victor ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Department of Paediatrics   (Sweden)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Arthropathy; Haemophilia; Imaging; Inhibitors; Joint; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CYTOKINE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STROMAL CELL DERIVED FACTOR 1; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN A;

ANALGESIA; ARM MOVEMENT; ARTHRALGIA; ARTICLE; CARTILAGE; CLINICAL ASSESSMENT TOOL; DISEASE DURATION; ECHOGRAPHY; FUNCTIONAL ASSESSMENT; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOPHILIC ARTHROPATHY; HEMOSTASIS; HISTOPATHOLOGY; HUMAN; INFLAMMATION; JOINT DESTRUCTION; JOINT FUNCTION; JOINT RADIOGRAPHY; JOINT SWELLING; MOLECULAR IMAGING; MUSCLE ATROPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATELLA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; SELF CARE; SOFT TISSUE; SYNOVIAL FLUID; SYNOVIOCYTE; VEIN PUNCTURE; WOUND HEALING;

ACTIVITIES OF DAILY LIVING; BLOOD COAGULATION FACTORS; DISABILITY EVALUATION; HEMARTHROSIS; HEMOPHILIA A; HUMANS; QUALITY OF LIFE;

EID: 84863544652     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02888.x     Document Type: Article

References (67)

1. Mackman N. Tissue-specific hemostasis in mice. Arterioscler Thromb Vasc Biol 2005; 25: 2273-81.
2. Dunn AL. Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia. Haemophilia 2011; 17: 571-8.
3. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12: 117-21.
4. Acharya SS, Kaplan RN, Macdonald D, Fabiyi OT, DiMichele D, Lyden D. Neoangiogenesis contributes to the development of hemophilic synovitis. Blood 2011; 117: 2484-93.
5. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
6. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
7. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
8. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost 2007; 5: 1577-83.
9. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood 2006; 108: 3053-60.
10. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia 2006; 12: 654-62.
11. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008; 14: 804-9.
12. Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood 2008; 112: 4532-41.
13. Valentino LA, Hakobyan N, Kazarian T, Sorensen BB, Tranholm M. Prevention of haemarthrosis in a murine model of acute joint bleeding. Haemophilia 2009; 15: 314-9.
14. Monahan PE, Sun J, Gui T, Wichlan DG, McPhee SW, Samulski RJ. Employing factor IX variants to avoid limitations imposed by immune recognition of AAV vector in hemophilia B gene therapy. Blood 2011; 118: Abstract 3124.
15. Thomsen MK, Wildgoose P, Nilsson P, Hedner U. Accumulation of the recombinant factor VIIa in rat bone: importance of the Gla-domain and relevance to factor IX, another vitamin K-dependent clotting factor. Pharmacol Toxicol 1993; 73: 127-32.
16. Beeby TL, Chasseaud LF, Taylor T, Thomsen MK. Distribution of the recombinant coagulation factor 125I-rFVIIa in rats. Thromb Haemost 1993; 70: 465-8.
17. Gopalakrishnan R, Hedner U, Ghosh S et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2009; 8: 301-10.
18. Karlström E, Norgård M, Hultenby K et al. Localization and expression of prothrombin in rodent osteoclasts and long bones. Calcif Tissue Int 2011; 88: 179-88.
19. Sun J, Hu G, Monahan PE. TNF-alpha antagonists augment factor replacement to prevent arthropathy in hemophilic mice. J Thromb Haemost 2009; 7(Suppl. 2): 225 Abstract OC-WE-064.
20. Jansen NW, Roosendaal G, Hooiveld MJ et al. Interleukin-10 protects against blood-induced joint damage. Br J Haematol 2008; 142: 953-61.
21. Kisker CT, Burke C. Double-blind studies on the use of steroids in the treatment of acute hemarthrosis in patients with hemophilia. N Engl J Med 1970; 282: 639-42.
22. Medeiros D, Laufenberg JA, Miller KL, Buchanan GR. Short-term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high-titre inhibitors. Haemophilia 2007; 13: 85-9.
23. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am 1977; 59: 287-305.
24. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; 149: 153-9.
25. Doria AS, Kraft J, Babyn P, Demers C, Israelis S, Pai M. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in a multicentre clinical trial in Canada. Pediatr Radiol 2011; 41: S291 [Abstract].
26. Nuss R, Kilcoyne RF, Geraghty S et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6: 162-9.
27. Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004; 10: 383-9.
28. Dobón M, Lucía JF, Aguilar C et al. Value of magnetic resonance imaging for the diagnosis and follow-up of haemophilic arthropathy. Haemophilia 2003; 9: 76-85.
29. Soler R, Lopez-Fernandez F, Rodriguez E, Marini M. Hemophilic arthropathy. A scoring system for magnetic resonance imaging. Eur Radiol 2002; 12: 836-43.
30. Mathew P, Talbut DC, Frogameni A et al. Isotopic synovectomy with P-32 in paediatric patients with haemophilia. Haemophilia 2000; 6: 547-5.
31. Funk MB, Schmidt H, Becker S et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002; 8: 98-103.
32. Lundin B, Babyn P, Doria AS et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11: 109-15.
33. Merchan EC, De Orbe A, Gago J. Ultrasound in the diagnosis of the early stages of hemophilic arthropathy of the knee. Acta Orthop Belg 1992; 58: 122-5.
34. Zukotynski K, Jarrin J, Babyn PS et al. Sonography for assessment of haemophilic arthropathy in children: a systematic protocol. Haemophilia 2007; 13: 293-304.
35. Muça-Perja M, Riva S, Grochowska B, Mangiafico L, Mago D, Gringeri A. Ultrasonography of haemophilic arthropathy. Haemophilia 2012; 18: 364-8.
36. Doria AS, Chaudry GA, Nasui C et al. The use of parallel imaging for MRI assessment of knees in children and adolescents. Pediatr Radiol 2010; 40: 284-93.
37. Magee T, Shapiro M, Williams D. Comparison of high-field-strength versus low-field-strength MRI of the shoulder. Am J Roentgenol 2003; 181: 1211-5.
38. Eckstein F, Siedek V, Glaser C et al. Correlation and sex differences between ankle and knee cartilage morphology determined by quantitative magnetic resonance imaging. Ann Rheum Dis 2004; 63: 1490-5.
39. Al-Ali D, Graichen H, Faber S, Englmeier KH, Reiser M, Eckstein F. Quantitative cartilage imaging of the human hind foot: precision and inter-subject variability. J Orthop Res 2002; 20: 249-56.
40. Thompson RS, Trudinger BJ, Cook CM. Doppler ultrasound waveform indices: A/B ratio, pulsatility index and Pourcelot ratio. Br J Obstet Gynaecol 1988; 95: 581-8.
41. Dardzinski BJ, Schmithorst VJ, Holland SK et al. MR imaging of murine arthritis using ultrasmall superparamagnetic iron oxide particles. Magn Reson Imaging 2001; 19: 1209-16.
42. Doria A, Amirabadi A, Miller E, Cheng H, Zhong A, Sussman M. Functional-molecular magnetic resonance imaging for early characterization of hemophilic arthropathy in a rabbit model. Haemophilia 2010; 16: 72 [Abstract 17P28].
43. Shammas A, Charron M, Metser U, Amirabadi A, Zhong A, Doria AS. [18-F] Fluorodeoxyglucose (FDG) positron emission tomography (PET) for detection of hemophilic arthropathy in a rabbit model. Haemophilia 2010; 16: 78 [Abstract 17P65].
44. Nieminen MT, Rieppo J, Silvennoinen J et al. Spatial assessment of articular cartilage proteoglycans with Gd-DTPA-enhanced T1 imaging. Magn Reson Med 2002; 48: 640-8.
45. Glaser C. New techniques for cartilage imaging: T2 relaxation time and diffusion-weighted MR imaging. Radiol Clin North Am 2005; 43: 641-53, vii.
46. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Haematol 1993; 30: 3-6.
47. Hilliard P, Funk S, Zourikian N et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518-25.
48. Feldman BM, Funk SM, Bergstrom BM et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res 2011; 63: 223-30.
49. Poonnoose PM, Manigandan C, Thomas R et al. Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia 2005; 11: 598-602.
50. van Genderen FR, Westers P, Heijnen L et al. Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12: 36-46.
51. Groen WG, van der Net J, Helders PJ, Fischer K. Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List (PEDHAL). Haemophilia 2010; 16: 281-9.
52. von Mackensen S, Czepa D, Herbsleb M, Hilberg T. Development and validation of a new questionnaire for the assessment of subjective physical performance in adult patients with haemophilia - the HEP-Test-Q. Haemophilia 2010; 16: 170-8.
53. von Mackensen S, Bullinger M; on behalf of the Haemo-QoL Group. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10: 17-25.
54. Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia? Pediatr Blood Cancer 2006; 47: 305-11.
55. Rentz A, Flood E, Altisent C. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia 2008; 14: 1023-34.
56. Remor E, Arranz P, Quintana M et al. Psychometric field study of the new haemophilia quality of life questionnaire for adults: the 'Hemofilia-QoL'. Haemophilia 2005; 11: 603-10.
57. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
58. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
59. Parameswaran R, Shapiro AD, Gill JC, Kessler CM; HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
60. Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag 2007; 3: 527-31.
61. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
62. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
63. -1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
64. Kavakli K, Makris M, Zulfikar B et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
65. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
66. -1) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia 2009; 15: 760-5.
67. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-9.